Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, do people have to stop vaping for XXII to fail marketing VLN? I think not! That's all that matters. The fact is, they will be vaping MJ soon if its not happening now. XXII needs to get with the program to monetize their patents before the opportunity is gone: that's with tobacco or MJ. NOW!!!
XXII is named the best penny pot stock...that's why this is up.
High $6 price target...bye bye $5
https://mailchi.mp/cannaroyalty/cannaroyalty-investor-updates-sep2018
Lustig will be on a conference tomorrow. More eyes will be on this one. Good start of the week. Testing another 52 week high!
NIce! Envious! I got too excited on the 5.70 from 5.9 lol! No worries!
This was an aftermarket news that will affect their bottom line in Canada in preparation for the Oct 17 event! Up we go tomorrow. Don’t worry too much about this co. It isn’t hyped as the other weed stocks. Only worry if you aren’t in it enough when it flys and you can no longer afford it. :)
Please tell me what would the possibilities of a news that would drop this? Dilution? They just reported a good quarter; possibly a partner dropped out? What are the chances really? So me guess the other way around NORTH... more possible explanations. Truly undervalued!
Sheezz, we got the patents...they have no choice!
Why not BT with weed? Makes more sense than drinking the damn thing!
XXII doesn't really parade itself as a MJ stock. Most people out there can't connect the dots between Aurora and XXII. But then again, there is the current fed ruling still here. So, here we are floating around like a ...
This headline even better! Buy the DIPS!
https://insiderfinancial.com/cannaroyalty-corp-otcmktscnnrf-wait-pullbacks
What did I tell you!!! BUY any dips!! HOD keeps going up!
Someone forward that to Henry and the Doctor G., so we don’t have to wait for ecigs and any other drugs to pass FDA for reducing the withdrawal symptoms caused by drastically reducing nicotine as a standard. XXII just have to lace their sticks with CBD and market it around the world!! Sounds good but may become controversial without further studies I’m sure, but sounds promising!
With Oct. 17, where do you think it's gonna go? ONly fools get spooked! This co. has enough cash and increasing revenue yr over yr...and projected revenues for the next quarters will circumnavigate the previous with RVR and Alta completion.
And compared to other pot stocks, this didn't do bad at all. It surprisingly held up. AND... We got our $5.49 = the 52 wk high yesterday before it went down!!! It went down only 3.86%? Buy all dips!
There’s your breakout!!! If we sustain this volume, $3 will be in the picture soon!
Been eyeing this since summer. Finally bought a couple to thousand shares on the dip a couple of days ago. The company executes very well on their plan. They have the right targets of CA and next Nevada. Exciting prospects and will love to see how it unfolds! With this little outstanding shares, this will be a double digit stock in no time.
Thanks TT, but here is a clearer picture of XXII on Aurora.
Anandia Laboratories Investment
22nd Century had invested in research partner, Anandia Laboratories in Canada, but that cannabis company has agreed to be acquired by Aurora Cannabis Inc. (ACBFF) 22nd Century will now receive shares of Aurora Cannabis in return for its approximately 14.8% equity ownership of Anandia. So, in a way 22nd Century Group will have some investment into a real cannabis company by owning shares of Aurora Cannabis.
https://www.greenmarketreport.com/blackrock-increases-its-cannabis-investing/
We are on the POT radar again...
https://investorplace.com/2018/09/marijuana-stocks-to-buy-pot-craze/
One may think; lets hope we hear from the feds soon!
It wasn't Gottlieb that ran the FDA then was it? THat's the difference.
Nothing is tomorrow with this company. Just thinking of ideas of how we can get ahead without waiting for BT and FDA to line up.
I just quickly glanced at the after hours trading...looking good. But then again, that doesn't always mean anything.
Bbbbut, it’s not news that they used the Spectrun for these studies. Why would it go boom now, it didn’t go boom the first time XXII got mentioned? Sound too much of investors tweeting. And that vapor guy? He said he’s tried everything to quit... I highly doubt he tried doing it in the act of smoking as these VLN’s would yield. Smell and taste are too powerful to give up which patches and gums can’t replace. That’s why he is vaping... just like any orally fixated person . Now how about a SPECTRUM prescription for the MD to recommend? If not over th counter?
Review: I think the market is anticipating this...
https://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Documents/2018_05_21_Nicotine_Product_Standard_Letter.pdf
Finally, FDA’s own estimates of the lifesaving potential of your nicotine reduction proposal require a sense of urgency commensurate with that potential. Every day that passes means more kids moving from experimentation to addiction and more adults who want to quit and try to quit, but remain addicted to a lethal product. We urge FDA to issue a proposed rule within six months of its ANPRM (by September 16, 2018) and a final rule six months later (by March 16, 2019). We also urge that implementation of the rule be no later than the one-year period provided for in Section 907 of the Family Smoking Prevention and Tobacco Control Act, which would allow the rule to be implemented by March of 2020.
Thumbs up! Although XXII is a flat liner today!
Let's say we submit MRTP by end of year and the FDA fast track it...how many months away does that mean? Anyone?
Up we go tomorrow!
The whole market is red, not just us...this should be a good bounce buying opp!
This is why we're up!
Cannabis Market Expected to Grow With Incorporation of Online Retailers
9:00 am ET August 27, 2018 (PR Newswire) Print
According to research published by Technavio, the legal cannabis market is estimated to grow at a steady CAGR of about 24% until 2021. The increasing popularity of cannabidiol (CBD) oil products is a major growth factor for this young industry. In addition, the wide reach of online retailers is also projected to contribute significantly to the legal cannabis market. Technavio also points out that modern customers would rather pay using digital payment solutions, saving time and billing queues. As a result, manufacturers and marketers are turning their attention towards the internet-savvy consumer segment and new online retail formats are set to become an unexpected innovative force. CLS Holdings USA Inc. (OTC: CLSH), Invictus MD Strategies Corp. (OTC: IVITF), 22nd Century Group Inc. (NYSE: XXII), Emerald Health Therapeutics Inc. (OTC: EMHTF), Cannabis Sativa Inc. (OTC: CBDS)
Despite the growing popularity of the market, education on cannabis products and their applications remains minimal. The Mount Royal University in Alberta, Canada announced recently that it is partnering with Kwantlen Polytechnic University to offer three, non-credit, online courses on the business of cannabis. According to CBC, Brad Mahon, Dean of the Faculty of Continuing Education at Mount Royal University, explained that, "The idea was, we have a lot of courses connected to business and professional education, so this seemed like really, a natural fit; There is already a demand for the courses. We expect people who are kind of tire kickers, people who are curious and want to learn a little bit more, and we also expect people who are serious about learning more about this new industry. In many ways, these are business courses."
CLS Holdings USA Inc. (OTCQB: CLSH) earlier last week announced breaking news that, "Matthew Janz has joined the Company as VP of Marketing and Director of Operations at Oasis Cannabis.
Mr. Janz, previously the Regional Marketing Manager at Apothecarium, will lead the new marketing initiative programs at Oasis Cannabis, with a focus in digital marketing and social media engagement, and with attention to creative tact. He will orchestrate and implement all SEO, SEM, E-mail, Social, and AdWord work.
Matthew Ganz, VP of Marketing and Director of Operations at Oasis Cannabis, stated, 'I am excited to be a part of the Oasis Cannabis team. My expertise of creating innovative marketing solutions has been very successful in the cannabis industry with consistent conversions and building long-term growth. I'm looking forward to continuing that work with Oasis and helping improve their visibility, awareness and market penetration in the Las Vegas market.'
Jeff Binder, Chief Executive Officer of CLS, commented, 'I am pleased to welcome Matt to our CLS and Oasis team. Given his previous success at Apothecarium, we are confident in his marketing abilities and believe he will make key improvements in our marketing strategy. We look forward to the increased visibility for Oasis as we look to expand the growth opportunities for Oasis and CLS.'
About Oasis Cannabis (https://oasiscannabis.com/ ): Oasis Cannabis has operated a cannabis dispensary in the Las Vegas market since dispensaries first opened in Nevada in 2015 and has been recognized as one of the top marijuana retailers in the state. Its location within walking distance to the Las Vegas Strip and Downtown Las Vegas in combination with its delivery service to residents allows it to efficiently serve both locals and tourists in the Las Vegas area. The company recently commenced wholesale offerings of cannabis in Nevada with the launch of its City Trees brand of cannabis concentrates and cannabis-infused products in August 2017. An expansion of its cultivation and production facility is currently underway and is expected to be completed during the fourth quarter of 2018."
Invictus MD Strategies Corp. (OTCQX: IVITF) is a global cannabis company offering a selection of products under a wide range of lifestyle brands. Our integrated sales approach is defined by five pillars of distribution including medical, wholesale, international, Licensed Producer to Licensed Producer and retail. Earlier this month, the Company announced that is has signed a commitment letter for a USD 25.5 Million debt financing arrangement with an interest rate at prime plus 2% per annum with ATB Financial to accelerate the construction of its Phase 3 and Phase 4 cannabis cultivation facilities at Acreage Pharms Ltd., located in West-Central Alberta. The Expansion Plan will add a total of 180,000 sq. ft. of production capacity to Acreage Pharms. The Phase 3 expansion is underway with over USD 3 Million in progress payments already made for permitting, lot preparation, foundation construction and precast installation. Phase 3 has a target completion date of January 2019 and will bring the Company's gross cultivation space to 200,000 sq. ft. Phase 4 will be completed by mid-2019.
22nd Century Group Inc. (NYSE: XXII) is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The Company's primary mission in hemp/cannabis is to develop proprietary hemp strains for important new medicines and agricultural crops. 22nd Century's wholly-owned subsidiary, Botanical Genetics LLC, entered into a worldwide license agreement with Anandia Laboratories Inc. Under the terms of the agreement, the Company was granted an exclusive sublicense in the United States and a co-exclusive sublicense in the remainder of the world, excluding Canada, to patents and patent applications relating to the cannabis plant that are required for the production of cannabinoids, the major active ingredients in the cannabis plant. The Anandia sublicense continues through the life of the last to expire patent, which is expected to be 2035.
Emerald Health Therapeutics Inc. (OTCQX: EMHTF) is licensed in Canada to produce and sell dried cannabis and cannabis oil for medical purposes. Recently, the Company announced that their 50/50 joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its third amendment to the cultivation license for its Delta 3 greenhouse in Delta, BC. This amendment permits Pure Sunfarms to expand its cannabis production area by 195,000 sq. ft. to approximately 420,000 sq. ft. of the 1.1 Million sq. ft. Delta 3 production facility. The newly licensed area will be in commercial production this week, as the Delta 3 nursery has been producing cuttings in anticipation of this expansion. Pure Sunfarms expects to have the full 1.1 Million sq. ft. Delta 3 facility, one of the single largest cannabis growing facilities in the world, converted for cannabis production by year-end.
Cannabis Sativa Inc. (OTCQB: CBDS) is engaged in the licensing of cannabis-related intellectual property, marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. Earlier this year, the Company announced that PrestoDoctor(R), the leading online medical marijuana recommendation service, will be expanding to Pennsylvania on April 20th, 2018. More than 3,800 people have signed up in the medical marijuana patient registry's first week, signaling strong statewide interest in the program that will give those with one of 17 specific diagnoses access to cannabis beginning next year. PrestoDoctor(R) is addressing the lack of physicians with its #1 ranked telemedicine platform, which streamlines much of the process. Prospective patients simply fill out a short online application, choose an appointment time, and talk to a physician.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For CLS Holdings USA Inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated five thousand dollars by the company Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com .
Media Contact: info@financialbuzz.com +1-877-601-1879
Url: www.FinancialBuzz.com
SOURCE FinancialBuzz.com
https://rt.prnewswire.com/rt.gif?NewsItemId=enUK201808270980&Transmission_Id=201808270900PR_NEWS_USPR_____enUK201808270980&DateId=20180827
Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.
Market data and information provided by Morningstar.
Well, if L2 was lying, u would be right.
Hmmm... me thought I saw Blackrock buying big blocks today. Confidence into the 3 day weekend!
Nice find! We may have news coming? One out of two study completion is pretty weak reason though.
What’s fueling this today? Huge buys!
Wait up! I must be out of the loop here. What else do we have on MJ now that Anandia is now owned by Aurora? I didn’t listen to last cc, so I don’t know if that was discussed. What IP? XXII’s MJ is now a blur to me since that buy out by Aurora. Can one clarify our position in the MJ market?
This should be a slap on FDA ‘s face! While Gottlieb and FDA is stalling, several agencies mention here how accelerated these vaping products are coming to market. And most products are from Big Tobacco themselves!!!! Seems to me FDA is all talk, and and slow to act. Glad we’re not the only one noticing it!
https://www.tobaccofreekids.org/assets/content/press_office/2018/2018_08_07_new_ecig_products.pdf
Agree, and agree! I’ve watched their sell and buy signals to be too late for the party or for escape. Very bad indicator.
Just wondering why we can’t just bypass US and go to market in let’s say India or Australia?? ... that wouldn’t require an MRTP app.
Could there have been a clause that since the feds funded-our VLN trials and etc, that we can’t market this to other countries first ?